Table 1.
Baseline characteristics
| Healthy Controls (n = 8) | Fabry Disease Patients (n = 38) | p-value | |
|---|---|---|---|
| Age (years) | 40.1 ± 13.7 | 45.0 ± 14.5 | 0.39 |
| Female | 3 (38%) | 24 (63%) | 0.25 |
| Male | 5 (63%) | 14 (37%) | 0.25 |
| Hematocrit (%) | 41 ± 5 | 41 ± 4 | 0.96 |
| Height (cm) | 168.0 ± 14.0 | 166.5 ± 9.3 | 0.71 |
| Weight (kg) | 72.3 ± 15.1 | 75.2 ± 15.8 | 0.64 |
| BSA (m2) | 1.83 ± 0.25 | 1.85 ± 0.21 | 0.81 |
| Systolic blood pressure (mmHg) | 120.6 ± 15.1 | ||
| Diastolic blood rpessure (mmHg) | 76.9 ± 9.5 | ||
| Hypertension | 13 (34%) | ||
| Diabetes mellitus | 2 (5%) | ||
| Chronic kidney disease | 0 (0%) | ||
| Medications | |||
| Enzyme replacement therapy | 13 (34%) | ||
| Beta blockers | 6 (16%) | ||
| Statins | 17 (45%) | ||
| Calcium channel blocker | 4 (11%) | ||
| ACEi/ARB | 15 (40%) | ||
| Aspirin | 15 (40%) |
Comparisons between groups were made by independent samples t-test, Wilcoxon rank sum test or Fisher’s exact test. Continuous variables are presented as mean ± SD. Categorical variables are presented as number of subjects with percentage in parentheses. ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BSA body surface area